Heron Therapeutics (NASDAQ: HRTX) announced that data from Heron’s recently completed MAGIC Study of SUSTOL (granisetron) Injection, extended release, for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE